Infant Bacterial Therapeutics AB (STU:9IB) Other Operating Expense : €-0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB Other Operating Expense?

Infant Bacterial Therapeutics AB's Other Operating Expense for the three months ended in Dec. 2024 was €-0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.00 Mil.

Infant Bacterial Therapeutics AB's quarterly Other Operating Expense increased from Jun. 2024 (€-0.00 Mil) to Sep. 2024 (€0.00 Mil) but then declined from Sep. 2024 (€0.00 Mil) to Dec. 2024 (€-0.00 Mil).

Infant Bacterial Therapeutics AB's annual Other Operating Expense declined from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€-0.01 Mil) but then increased from Dec. 2023 (€-0.01 Mil) to Dec. 2024 (€-0.00 Mil).

Infant Bacterial Therapeutics AB Other Operating Expense Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Other Operating Expense Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Operating Expense

Get a 7-Day Free Trial

-0.03

-0.01

Infant Bacterial Therapeutics AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

Infant Bacterial Therapeutics AB Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

Infant Bacterial Therapeutics AB Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

IBT B:Sweden

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines